Arthritis clinical trials at UCSF

• Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

  open to eligible people ages 18 years and up

  This study is an evaluation of the precision and sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Planar Imaging

  San Francisco, California and other locations

• Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

  open to eligible people ages 2-16

  This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form.To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

  San Francisco, California and other locations

• Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

  open to eligible people ages 18 years and up

  The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels: -Pre-screening: - first degree relatives of patients with rheumatoid arthritis (RA); - subjects at health-fairs; and - identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.

  San Francisco, California and other locations

• Treatments Against RA and Effect on FDG-PET/CT

  open to eligible people ages 45 years and up

  In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).

  San Francisco, California and other locations

• Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

  Sorry, currently not accepting new patients, but might later

  This is a single center exploratory imaging study investigating the initial application of 89Zr-DFO-CZP PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.

  San Francisco, California

• Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

  Sorry, in progress, not accepting new patients

  The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

  San Francisco, California and other locations

• Pediatric Arthritis Study of Certolizumab Pegol

  Sorry, in progress, not accepting new patients

  A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

  San Francisco, California and other locations

Last updated: August 31, 2020